Exclusive

Publication

Byline

Global Brand and Leadership Conclave 2026 by The Brand Story Celebrates Excellence at the Iconic House of Lords, British Parliament, London

New Delhi, June 9 -- London [United Kingdom], June 9 : The Global Brand and Leadership Conclave 2026, hosted at the iconic House of Lords, British Parliament, Londonrecognised outstanding brand... Read More


Senate canvasses total ban on textile imports, pushes for revival of sector

Nigeria, June 9 -- The Senate on Wednesday called for a total ban on the importation of textile products to enable Nigeria's local textile industry to thrive, create jobs, and generate more revenue fo... Read More


Startup founder reacts with inappropriate emoji after candidate cancels interview

India, June 9 -- A candidate seeking an internship recently took to social media to call out a startup founder's allegedly shockingly unprofessional behaviour. After researching the business and feeli... Read More


Patna Court protects Khan Sir from arrest as guards who fired outside his institute face charges

New Delhi, June 9 -- The Patna District Court on Tuesday granted an interim stay on the arrest of educator Faisal Khan, widely known as Khan Sir, providing the prominent coaching figure with temporary... Read More


Pressure mounts on INEC over delayed delineation of Warri Federal Constituency

Nigeria, June 9 -- Pressure is mounting on the Independent National Electoral Commission (INEC) to explain the delay in implementing its final delineation report for Warri Federal Constituency. A gro... Read More


Singapore Clinical Trial: A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solution for Injection (TLX101-Tx) Plus Lomustine Versus Lomustine Alone in Patients with Radiographically Confirmed Recurrent Glioblastoma at First Recurrence (IPAX-3)

Singapore, June 9 -- The Health Sciences Authority received information related to the study titled 'A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Soluti... Read More


Singapore Clinical Trial: RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma

Singapore, June 9 -- The Health Sciences Authority received information related to the study titled 'RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Mo... Read More


Singapore Clinical Trial: A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors, including Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors

Singapore, June 9 -- The Health Sciences Authority received information related to the study titled 'A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembro... Read More


Singapore Clinical Trial: A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension (PALM-PAH)

Singapore, June 9 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter, Parallel-group Study to Evalu... Read More


Singapore Clinical Trial: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1)

Singapore, June 9 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and ... Read More